RESOLUTION THERAPEUTICS LIMITED

• ⚠

  Material uncertainty over going concern

  These conditions indicate the existence of a material uncertainty which may cast significant doubt about the company's ability to continue as a going concern, such that it may be unable to realise its assets and discharge its liabilities in the normal course of business. The financial statements do not include the adjustments that would result if the company was unable to continue as a going concern, therefore the financial statements have been prepared on a going concern basis.

1. RESOLUTION THERAPEUTICS LIMITED 2020-07-30 → present
2. SYNCONA COLLABORATION (E) LIMITED 2017-12-14 → 2020-07-30

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

RSM UK Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“These conditions indicate the existence of a material uncertainty which may cast significant doubt about the company's ability to continue as a going concern, such that it may be unable to realise its assets and discharge its liabilities in the normal course of business. The financial statements do not include the adjustments that would result if the company was unable to continue as a going concern, therefore the financial statements have been prepared on a going concern basis.”

Group structure

1. RESOLUTION THERAPEUTICS LIMITED · parent
   1. Resolution Therapeutics US LLC 100% · US

Significant events

• “Following initial seed funding of £1.4m in January 2018, the company raised Series A funding totalling £36.5m from Syncona Ltd to fund its initial drug development activities.”
• “In March 2024 the company issued a £12m convertible loan note to Syncona Ltd.”
• “In September 2024 Resolution successfully completed a Series B fundraise totalling £63.5m with Syncona Ltd, including the conversion of the £12m convertible loan note and accrued interest.”
• “In March 2025, a convertible loan note of £9m was drawn from Syncona Ltd.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

12

last 12 months

Capital events

7

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  +10.1%

  £13,817,911 → £15,211,685

• Net assets

  +86.9%

  £4,050,368 → £7,569,356

• Employees

  -2.9%

  70 → 68

• Operating profit

  -18.8%

  -£17,710,354 → -£21,041,105

• Profit before tax

  -18.8%

  -£17,710,354 → -£21,041,105

• Wages

  +27.1%

  £4,748,390 → £6,035,643

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers